CD9, a tetraspanin target for cancer therapy?

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

Abstract

In the present minireview, we intend to provide a brief history of the field of CD9 involvement in oncogenesis and in the metastatic process of cancer, considering its potential value as a tumor-associated antigenic target. Over the years, CD9 has been identified as a favorable prognostic marker or predictor of metastatic potential depending on the cancer type. To understand its implications in cancer beside its use as an antigenic biomarker, it is essential to know its physiological functions, including its molecular partners in a given cell system. Moreover, the discovery that CD9 is one of the most specific and broadly expressed markers of extracellular membrane vesicles, nanometer-sized entities that are released into extracellular space and various physiological body fluids and play a role in intercellular communication under physiological and pathological conditions, notably the establishment of cancer metastases, has added a new dimension to our knowledge of CD9 function in cancer. Here, we will discuss these issues as well as the possible cancer therapeutic implications of CD9, their limitations, and pitfalls.

Details

Original languageEnglish
Pages (from-to)1121-1138
JournalExperimental biology and medicine : EBM
Volume246
Publication statusPublished - 18 Feb 2021
Peer-reviewedYes

External IDs

PubMed 33601913
Scopus 85101229025
ORCID /0000-0001-7687-0983/work/142253714

Keywords

Sustainable Development Goals